Neogenomics Laboratories

NeoGenomics News

IMPORTANT MESSAGE – NeoLINK - Limited Functionality within Internet Explorer

As you may be aware, starting June 15, 2022, the Internet Explorer 11 desktop application will no longer be supported by Microsoft.  As a result, effective 04/25/2022, NeoGenomics Laboratories will no longer ensure NeoLINK is compatible within any version of Internet Explorer.  Customers using Internet Explorer may experience loss of functionality while navigating throughout NeoLINK.      

Customers are encouraged to move to Microsoft Edge, which provides support for legacy and modern websites and apps.  Google Chrome is also an acceptable and supported alternative. 

If you have any questions or concerns please contact NeoGenomics Client Services at 866-776-5907, Option 3.

Thank you,

IT Development and Security, NeoGenomics Laboratories

5/18/22

Test Updates

Requirement of NPI Number with Orders

Starting July 2022, NPI numbers of both Ordering and Treating Physicians will be required on all orders with NeoGenomics across all platforms (paper requisitions, online orders, and interfaced orders). NPI numbers are important for report distribution and billing accuracy. If possible, please make all necessary preparations by July 2022 to ensure your orders will be completed with appropriate NPI numbers. Please stay tuned for further info and reminders from your Neo Sales Consultants and NeoNEWS. For any questions, please contact our Client Services team at 1.866.776.5907 option 3.

 

Molecular

FLT3 Testing with NeoTYPE® Heme ProfilesEffective Monday, June 6, FLT3 by PCR (via FLT3 Mutation Analysis) will be available to be ordered, as Client-Bill only, in conjunction with the following NeoTYPE® Heme Profiles:

  • NeoTYPE® AML Prognostic Profile
  • NeoTYPE® MDS/CMML Profile
  • NeoTYPE® Myeloid Disorders Profile

It will be an additional test order and reported separately from the NeoTYPE® Profile (which includes the FLT3 gene by NGS). This test combination is intended to be used for the purpose of prompt therapy selection in patients with a new diagnosis of AML.

Ordering options will be available as follows:

  • NeoTYPE® AML Prognostic Profile
  • NeoTYPE® AML Prognostic Profile (plus FLT3 by PCR)
  • NeoTYPE® MDS/CMML Profile
  • NeoTYPE® MDS/CMML Profile (plus FLT3 by PCR)
  • NeoTYPE® Myeloid Disorders Profile
  • NeoTYPE® Myeloid Disorders Profile (plus FLT3 by PCR)

Note: This new ordering structure will replace the current process which, by default, includes preliminary FLT3 testing by PCR with all orders of the aforementioned NeoTYPE® Profiles.

Please contact your local NeoGenomics Sales Consultant or our Client Services team at 1.866.776.5907 option 3 for pricing.

 

Update to NeoTYPE® Colorectal and Endometrial Profiles: Effective Monday, June 6th, MLH1 Promoter Methylation Analysis will be removed from these two solid tumor profiles. Microsatellite instability analysis and BRAF mutation analysis by NGS remain part of these profiles for Lynch Syndrome assessment and interpretation, respectively. Options to follow up MSI-high results include add-on MMR IHC and/or stand-alone MLH1 Promoter Methylation Analysis.

This change is part of ongoing efforts to maintain efficiency in our laboratory. No price or CPT code changes apply to the impacted NeoTYPE Profiles.

 

Interface Updates

For interface-related test changes taking effect on Monday June 6th, click here for a downloadable document to view the impacted interface test codes.


If you have interface questions, please contact InterfaceTeam@Neogenomics.com